JancsiTech Secures Tens of Millions in Angel+ Funding to Empower Intelligent Radiotherapy Equipment with Core Innovation

VCBeat has learned that Shenzhen Yangqi Yixin Intelligent Technology Co., Ltd. (hereinafter referred to as “Yangqi Medical”) has secured tens of millions of RMB in its Angel+ round of financing, co-led by HKX and Qiandao Fund, with follow-on investment from existing shareholder HongShan China Seed Fund. The funds raised in this round will be used to advance product iteration, drive technological innovation, and recruit top-tier radiotherapy talent from both domestic and international markets.

Yangqi Medical, established in September 2021 and headquartered in Shenzhen, has set up research and development centers in Shanghai and Hangzhou. The company is committed to becoming a pioneer in precision nuclear medicine. Its core founding team comprises experts in nuclear medicine, nuclear physics, and artificial intelligence from prestigious institutions such as Stanford University and Alibaba Group.

Yangqi Medical's Development History

With the gradual relaxation of licensing requirements for large-scale radiotherapy equipment, an increasing number of cancer patients can benefit from the advantages of non-invasive treatment and outpatient-based care. However, this also raises higher demands for the safety of the radiotherapy process and patient comfort. Currently, China faces a shortage of radiotherapy professionals, and the field is undergoing a critical transition from extensive to precision-based practices. Therefore, there is an urgent need for efficient and precise technological solutions to accelerate this transformation.

Yangqi Medical empowers precision radiotherapy through its independently developed optical navigation technology. By innovatively introducing non-contact tumor imaging technology, it scans the patient's body surface to acquire three-dimensional shape and positional information of the tumor without introducing additional radiation dose, thereby achieving high-precision localization. This assists physicians in formulating more accurate radiotherapy plans, ensuring that radiation is delivered exclusively to tumor tissue while minimizing damage to surrounding healthy tissues.

Real-time monitoring of tumor location and shape changes with high frame rate and high precision, enabling physicians to promptly adjust radiotherapy plans during treatment. This minimizes errors in tumor positioning caused by factors such as respiratory motion or weight loss, thereby delivering personalized treatment regimens for each patient.

The product integrates hardware and software to deliver precise radiation therapy, enabling physicians to perform procedures with greater accuracy and convenience while providing patients with an enhanced treatment experience and improved outcomes.

Currently, the company’s multiple core products have all achieved critical progress. Among them,Low-dose CT products are poised to obtain regulatory certification, having already been deployed for research and trial use at multiple hospitals and gaining recognition from leading CT manufacturers. The radiotherapy optical surface monitoring product, “Qi Shi,” has completed its R&D phase, entered the registration stage, and simultaneously commenced clinical research deployment and trials in hospitals. Moving forward, the company will continue to invest in R&D related to radiotherapy equipment, focusing on non-invasive radiotherapy technologies for superficial tumor treatment, while deeply cultivating the nuclear medicine sector in alignment with clinical needs.

Yangqi Medical's Product Matrix

Regarding this round of financing,Yangqi Medical Founding Teamstated: “It is a great honor to gain the recognition of both new and existing investors. With their expectations and support, Yangqi Medical will uphold its core values and strive to achieve precision radiotherapy through precise positioning, dose detection, and accurate beam delivery, thereby promoting the vigorous development of nuclear medicine. We are committed to sparing no effort in driving breakthroughs in nuclear medical technologies, bringing more precise and efficient treatment solutions to patients worldwide.”

Chen Yeyu, Investment Director of Hong Kong X Technology FundXiang stated, “Precision radiotherapy represents a global trend. As a low-cost mainstream treatment modality, radiotherapy has significant market potential in China, which has the largest cancer patient population worldwide yet currently exhibits a low rate of radiotherapy utilization. Developing cost-effective, domestically produced radiotherapy solutions is an inevitable choice for increasing radiotherapy coverage in China. Yangqi Medical’s business aligns well with Hong Kong’s medical advantages. HKX supports the team through strategic advice and resource matchmaking, assists in establishing a Hong Kong-based R&D company, and helps the company expand into international markets via Hong Kong. This initiative also serves as a practical example of HKX implementing the Hong Kong Special Administrative Region Government’s policy to ‘attract talent and enterprises.’ Through investment, it draws outstanding talents from renowned overseas universities to Hong Kong and facilitates the establishment of high-quality entrepreneurial teams in the region. The Yangqi Medical team focuses on precision nuclear medicine, and their dedication and execution capabilities are impressive. We believe the team can carve out an international path in precision nuclear medicine, bringing hope to patients worldwide.”

Qiandao Investment Fund Management (Beijing) Ltd.Co. stated: “Against the backdrop of an increasingly aging population and a growing sub-healthy population, market demand for oncology medical services is bound to continue rising. As a leading domestic player in next-generation AI-based precision radiotherapy technology, Yangqi Medical’s SGRT + dose monitoring solution can significantly shorten the radiotherapy cycle of current technologies, reduce radiation hazards to patients during treatment, lower health insurance expenditures, improve clinical efficiency, and facilitate the import substitution of high-end medical devices in China. Yangqi Medical has assembled a highly capable interdisciplinary team comprising top talents from renowned universities, which has effectively ensured the phased implementation of its products since inception. The R&D, sample submission, and type testing of its QiShi and QiJi product lines are all progressing as expected, and cooperation with leading listed domestic accelerator manufacturers is advancing smoothly. We look forward to the company’s early achievement of large-scale in-hospital product deployment, helping usher humanity into a new era of precision radiotherapy.”

Hong Kong X Technology Startup Platform was co-founded in Hong Kong by Mr. Neil Shen, Founding and Managing Partner of HongShan; Professor Li Zexiang of The Hong Kong University of Science and Technology; Professor Chen Guanhua of The University of Hong Kong; and 22 other leading professors and technology elites from Hong Kong.

The vision of the Hong Kong X Technology Entrepreneurship Platform is to inspire Hong Kong’s youth to engage in technological innovation and entrepreneurship, foster the prosperity of the innovation and technology ecosystem in Hong Kong and the Greater Bay Area, and facilitate the development of Hong Kong and the Guangdong-Hong Kong-Macao Greater Bay Area into an international hub for innovation and technology.

Hong Kong X Technology Fund Invests, an affiliate of the platform, focuses on investing in early-stage technology startups in Hong Kong and the Guangdong-Hong Kong-Macao Greater Bay Area.

HongShan China Seed Fund is a specialized investment fund under HongShan, focusing on angel and seed-stage investments. Since its establishment as an independent entity in 2018, the fund has strategically targeted early-stage structural innovation opportunities in technology, consumer, and healthcare sectors. It has invested in over 300 early-stage startups, many of which have grown into unicorns with valuations exceeding $1 billion.

Qiandao Group was founded in 2011. Upholding the philosophy of “integrating industry with finance and serving the nation through real economy,” it has deeply participated in China’s economic development and industrial upgrading, striving to become a comprehensive holding group led by technological innovation and dedicated to serving the real economy. The group comprises multiple member enterprises, including Qiandao Investment Fund Management (Beijing) Ltd.Co., which focuses on strategic emerging industries such as pharmaceuticals and medical technology, advanced manufacturing, and new energy and new materials, as well as China Xinxing Asset Management Co., Ltd., a subsidiary of a central state-owned enterprise undergoing mixed-ownership reform. These entities specialize in asset management and investment activities, including equity investment, industrial investment, and special opportunity investment.